Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy

Abstract

Introduction: Platinum (Pt)-based antitumor agents remain important chemotherapeutic agents for treating many human malignancies. Elevated expression of the human high-affinity copper transporter 1 (hCtr1), resulting in enhanced Pt drug transport into cells, has been shown to be associated with improved treatment efficacy. Thus, targeting hCtr1 upregulation is an attractive strategy for improving the treatment efficacy of Pt-based cancer chemotherapy.

Area covered: Regulation of hCtr1 expression by cellular copper homeostasis is discussed. Association of elevated hCtr1 expression with intrinsic sensitivity of ovarian cancer to Pt drugs is presented. Mechanism of copper-lowering agents in enhancing hCtr1-mediated cis-diamminedichloroplatinum (II) (cisplatin, cDDP) transport is reviewed. Applications of copper chelation strategy in overcoming cDDP resistance through enhanced hCtr1 expression are evaluated.

Expert opinion: While both transcriptional and post-translational mechanisms of hCtr1 regulation by cellular copper bioavailability have been proposed, detailed molecular insights into hCtr1 regulation by copper homeostasis remain needed. Recent clinical study using a copper-lowering agent in enhancing hCtr1-mediated drug transport has achieved incremental improvement in overcoming Pt drug resistance. Further improvements in identifying predictive measures in the subpopulation of patients that can benefit from the treatment are needed.

Keywords:

• Cisplatin
• copper chelators
• copper homeostasis
• hCtr1
• high-affinity copper transporter 1
• platinum drug cancer chemotherapy
• Sp1

Declaration of interest

The authors have been supported by grants from the National Science Council, Taiwan (NSC102-2628-B-006-014-MY3) (HHWC), and RO1 CA149260 (MTK, NS, and LGF) and R01 CA152197 (MTK) and CA16672 (MD Anderson Core) from the National Cancer Institute. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. We thank Michael Worley (Scientific Publications, MD Anderson Cancer Center) for editing the manuscript.

Notes

This box summarizes key points contained in the article.